US Food and Drug Administration Approval of Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis: A Model for Orphan Drug Development
Curr Infect Dis Rep
.
1999 Dec;1(5):415-416.
doi: 10.1007/s11908-999-0052-0.
Authors
RD Pearson
1
,
SM Jeronimo
,
SM Lareau
Affiliation
1
Box 485, Division of Geographic and International Medicine, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA.
PMID:
11095817
DOI:
10.1007/s11908-999-0052-0
No abstract available